JNJ

192.13

-0.88%↓

MDT

95.86

-0.14%↓

VEEV

289.87

+1.52%↑

A

145.91

+2.06%↑

HQY

95.86

+2.98%↑

JNJ

192.13

-0.88%↓

MDT

95.86

-0.14%↓

VEEV

289.87

+1.52%↑

A

145.91

+2.06%↑

HQY

95.86

+2.98%↑

JNJ

192.13

-0.88%↓

MDT

95.86

-0.14%↓

VEEV

289.87

+1.52%↑

A

145.91

+2.06%↑

HQY

95.86

+2.98%↑

JNJ

192.13

-0.88%↓

MDT

95.86

-0.14%↓

VEEV

289.87

+1.52%↑

A

145.91

+2.06%↑

HQY

95.86

+2.98%↑

JNJ

192.13

-0.88%↓

MDT

95.86

-0.14%↓

VEEV

289.87

+1.52%↑

A

145.91

+2.06%↑

HQY

95.86

+2.98%↑

Search

Recursion Pharmaceuticals Inc

Închisă

SectorSănătate

6.09 -8.7

Rezumat

Modificarea prețului

24h

Curent

Minim

5.99

Maxim

6.68

Indicatori cheie

By Trading Economics

Venit

31M

-172M

Vânzări

4.4M

19M

Marjă de profit

-899.843

Angajați

800

EBITDA

44M

-148M

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

-10.93% downside

Statistici piață

By TradingEconomics

Capitalizare de piață

356M

2.9B

Deschiderea anterioară

14.79

Închiderea anterioară

6.09

Sentimentul știrilor

By Acuity

100%

0%

355 / 371 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

Recursion Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

21 oct. 2025, 23:55 UTC

Acțiuni populare

Stocks to Watch: DraftKings, Texas Instruments, Intuitive Surgical, Pegasystems

21 oct. 2025, 23:49 UTC

Câștiguri

Texas Instruments Warns of Slower Semiconductor Industry Recovery -- Update

21 oct. 2025, 21:40 UTC

Câștiguri

Waste Connections 3Q Revenue Rises

21 oct. 2025, 21:14 UTC

Câștiguri
Principalele dinamici ale pieței

Intuitive Surgical 3Q Profit, Sales Jump, Sees Higher da Vinci Procedure Growth -- Update

21 oct. 2025, 21:05 UTC

Achiziții, Fuziuni, Preluări

GE Vernova to Acquire Full Stake in Prolec GE Joint Venture

21 oct. 2025, 20:57 UTC

Achiziții, Fuziuni, Preluări

DraftKings to Launch Prediction Markets Platform

21 oct. 2025, 20:38 UTC

Câștiguri

Intuitive Surgical 3Q Profit, Sales Jump, Sees Higher da Vinci Procedure Growth

21 oct. 2025, 20:35 UTC

Câștiguri

Capital One 3Q Sales, Profit Jump

21 oct. 2025, 20:32 UTC

Câștiguri

Texas Instruments 3Q Revenue Up on Growth Across End Markets

21 oct. 2025, 23:44 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

21 oct. 2025, 23:44 UTC

Market Talk

Nikkei May Rise on Weaker Yen, Hopes for Takaichi's Econ Steps -- Market Talk

21 oct. 2025, 23:39 UTC

Market Talk

Gold Consolidates; May Undergo Further Technical Correction -- Market Talk

21 oct. 2025, 23:36 UTC

Market Talk

BHP Has Hidden Leverage to Gold's Rush -- Market Talk

21 oct. 2025, 22:55 UTC

Achiziții, Fuziuni, Preluări

Scentre Says This Forms Part of Capital Management Strategy

21 oct. 2025, 22:55 UTC

Achiziții, Fuziuni, Preluări

Scentre: Continues to Evaluate Strategic Opportunities Including New JV Partners

21 oct. 2025, 22:54 UTC

Achiziții, Fuziuni, Preluări

Scentre Notes Media Report on Possible Sale of Stake in Westfield Chermside to Dexus Fund

21 oct. 2025, 21:09 UTC

Market Talk
Câștiguri

Netflix Creators Have Started Using AI in Production -- Market Talk

21 oct. 2025, 20:58 UTC

Market Talk
Câștiguri

Netflix Aims to Build on 'KPop Demon Hunters' Mania -- Market Talk

21 oct. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

21 oct. 2025, 20:50 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Financial Services Roundup: Market Talk

21 oct. 2025, 20:43 UTC

Câștiguri

Netflix Stock Drops After Earnings Miss Estimates -- Barrons.com

21 oct. 2025, 20:41 UTC

Câștiguri

Dow Industrials Hit Record, Boosted by Strong Earnings -- WSJ

21 oct. 2025, 20:33 UTC

Achiziții, Fuziuni, Preluări

GE Vernova: Deal Accelerates Growth for Electrification Segment >GEV

21 oct. 2025, 20:33 UTC

Achiziții, Fuziuni, Preluări

GE Vernova Acquiring Remaining 50% Stake of JV From Xignux >GEV

21 oct. 2025, 20:32 UTC

Achiziții, Fuziuni, Preluări

GE Vernova: Prolec GE Expects Low Double-Digit Rev Growth in Coming Years >GEV

21 oct. 2025, 20:32 UTC

Achiziții, Fuziuni, Preluări

GE Vernova: Prolec GE Expects $3B in Rev at 25% Adj EBITDA Margin in 2025 >GEV

21 oct. 2025, 20:32 UTC

Achiziții, Fuziuni, Preluări

GE Vernova: $5.275B Purchase Price at Closing, Expected to Be Funded Equally With Cash & Debt >GEV

21 oct. 2025, 20:32 UTC

Achiziții, Fuziuni, Preluări

GE Vernova Will Acquire Remaining 50% Stake of Prolec GE >GEV

21 oct. 2025, 20:31 UTC

Achiziții, Fuziuni, Preluări

GE Vernova To Fully Acquire Prolec GE Joint Venture >GEV

21 oct. 2025, 20:29 UTC

Câștiguri

Northrop Stock Tumbles on Sales Disappointment. When Good Isn't Good Enough. -- Barrons.com

Comparație

Modificare preț

Recursion Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

-10.93% jos

Prognoză pe 12 luni

Medie 5.95 USD  -10.93%

Maxim 8 USD

Minim 3 USD

În baza a 5 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruRecursion Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

5 ratings

1

Cumpărare

4

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

4.15 / 4.75Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Bearish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

355 / 371 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de scădere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
help-icon Live chat